EASI-SWITCH HARP-2 logo

Trial Acronym EASI-SWITCH
Clinical Area Cancer
Description Interventional study comparing whether early switch to oral antibiotics 12-24 hours after intravenous antibiotic treatment commences in patients with low risk of neutropenic sepsis is non-inferior to standard care. This is a randomised, controlled, non-inferiority trial with allocation concealment. Both arms of the trial will be conducted in parallel.
Status Open to recruitment
RECRUITMENT
Recruitment duration 1st January 2020
Target Recruitment 628
Recruitment to date 127 as of 07/11/2019
TRIAL DESIGN
Trial Design A multi-centre, interventional, randomised, controlled, non-inferiority trial with allocation concealment.
Study Aim To establish the clinical and cost-effectiveness of early switch to oral antibiotics, 12-24 hours after intravenous antibiotic treatment commences in low risk cancer patients with neutropenic sepsis.
CHIEF INVESTIGATOR (CI)
Chief Investigator Dr Victoria Coyle & Dr Ronan McMullan
SPONSOR(s) & FUNDER(s)
Sponsor Belfast Health and Social Care Trust
Funder National Institute for Health Research